Literature DB >> 8769735

Chronic increases in blood flow upregulate endothelin-B receptors in arterial smooth muscle.

D A Barber1, S R Michener, S C Ziesmer, V M Miller.   

Abstract

Experiments were designed to characterize endothelin receptors in arteries after chronic increases in blood flow. A fistula was created between the femoral artery and vein in one hindlimb of dogs; contralateral blood vessels were sham operated. Sham- and fistula-operated arteries were removed 6 wk postoperatively. Some arteries were prepared for measurement of isometric force or for isolation of membrane proteins. Other arteries were used for histological staining with an endothelin-B (ETB) receptor antibody. In arteries suspended for the measurement of isometric force, endothelin-1 produced concentration-dependent increases in tension that were significantly greater in fistula- than in sham-operated arteries without endothelium. The ETB-receptor-selective peptide sarafotoxin S6c produced concentration-dependent increases in tension only in fistula-operated arteries. In receptor-binding studies of membrane proteins, Scatchard analysis of saturation binding with 125I-labeled endothelin-1 (125I-endothelin-1) indicated that the total number of receptors was greater in fistula-operated arteries; affinity was threefold less in fistula- than in sham-operated arteries. Competitive displacement of 125I-endothelin-1 by endothelin-3 was significant for a two-site model in membranes prepared from sham-and fistula-operated arteries. Competitive inhibition of 125I-endothelin-1 binding by sarafotoxin S6c was significant for a one-site binding model in all arteries. Sarafotoxin S6c binding sites were elevated significantly in fistula-operated arteries. Immunohistochemical staining for the ETB receptor was significantly greater in both the endothelium and smooth muscle of fistula- than in sham-operated arteries. These results suggest that chronic increases in blood flow upregulate endothelin receptors, including ETB receptors in arterial smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769735     DOI: 10.1152/ajpheart.1996.270.1.H65

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

Review 1.  Structural basis of the function of endothelin receptor.

Authors:  T Masaki; H Ninomiya; A Sakamoto; Y Okamoto
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

2.  Regulation of the endothelin system by shear stress in human endothelial cells.

Authors:  H Morawietz; R Talanow; M Szibor; U Rueckschloss; A Schubert; B Bartling; D Darmer; J Holtz
Journal:  J Physiol       Date:  2000-06-15       Impact factor: 5.182

3.  Localization and function of ET-1 and ET receptors in small arteries post-myocardial infarction: upregulation of smooth muscle ET(B) receptors that modulate contraction.

Authors:  G A Gray; E J Mickley; D J Webb; P E McEwan
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

4.  Flow-mediated nitric oxide activity in the forearm vasculature of premenopausal women.

Authors:  Dilly O C Anumba; Stephen C Robson; Gary A Ford
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 5.  Sex-specific differences in hypertension and associated cardiovascular disease.

Authors:  Katrina M Mirabito Colafella; Kate M Denton
Journal:  Nat Rev Nephrol       Date:  2018-01-30       Impact factor: 28.314

6.  Increased expression of endothelin ET(B) and angiotensin AT(1) receptors in peripheral resistance arteries of patients with suspected acute coronary syndrome.

Authors:  Ivan Dimitrijevic; Ulf Ekelund; Marie-Louise Edvinsson; Lars Edvinsson
Journal:  Heart Vessels       Date:  2009-11-22       Impact factor: 2.037

7.  Deoxycorticosterone acetate-salt hypertensive rats display gender-related differences in ET(B) receptor-mediated vascular responses.

Authors:  R C Tostes Passaglia; F L David; Z B Fortes; D Nigro; R Scivoletto; M H Catelli De Carvalho
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.